Author:
Jiménez-González Carolina,Vallejo Ignacio,Sordo David,Medina-Méndez Juan Manuel,Alonso-Peña Marta,Crespo Javier
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809-2817.e28. https://doi.org/10.1016/j.cgh.2021.12.002.
2. Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural History of Nonalcoholic Fatty Liver Disease: A Prospective Follow-Up Study With Serial Biopsies. Hepatol Commun. 2017;2(2):199–210. https://doi.org/10.1002/hep4.113.
3. Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health. 2021;18(10):5227. https://doi.org/10.3390/ijerph18105227.
4. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497–509. https://doi.org/10.1056/NEJMoa2309000.
5. Madrigal Pharmaceuticals Announces FDA Approval of RezdiffraTM (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis —Full text view— https://www.madrigalpharma.com/. Available online: https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm (Accessed on 25 March 2024).